S2Medical AB (publ) (STO:S2M) Logo

About S2Medical AB (publ) (STO:S2M)

S2Medical AB (publ) develops, produces, and sells wound healing products for burns and chronic wounds in Sweden. It offers Epiprotect 2117, a synthetic allograft/xenograft substitute; Epiprotect Ulcer, a wound dressing consisting of a thin film of biosynthetic cellulose polymer intended to be used as a protective barrier for superficial wounds and deep wounds that have breached the dermis, as well as used as a temporary coverage for deep extensive wounds before transplantation or other surgical intervention. The company also provides washable, durable, waterproof, and self-adhesive bandages under the INSTABIND brand name, as well as NO SMELL, a perfume-free odour remover; BIOPAD, an ivory-white soft sponge; and INSTAQRETT, a sterile mechanical debridement tool for, among other things, multi-resistant Staphylococci. In addition, it offers IvaQ, CE-marked negative pressure wound therapy; Instagraft, designed to make advanced skin transplantation; ADMERCIN, next-generation antimicrobial peptide technology; Symbiovance, peptide-based functional skincare; Eyracure, a patented light-activated peptide technology that repairs damaged hair at the molecular level; and Eiratex, advanced biosynthetic polymer for next-generation wound healing applications. Further, the company operates the wound healing center under the S2Clinic name. The company was incorporated in 2013 and is headquartered in Linköping, Sweden.